Drug-induced osteoporosis: Beyond glucocorticoids

Current Rheumatology Reports

Volumn 10, Issue 2, 2008, Pages 102-109

  Briot, Karine ^a   Roux, Christian ^b  

^a Institut Cochin   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIVITAMIN K; AROMATASE INHIBITOR; ATYPICAL ANTIPSYCHOTIC AGENT; BUMETANIDE; CYCLOSPORIN; EXEMESTANE; GLITAZONE DERIVATIVE; GLUCOCORTICOID; GONADORELIN AGONIST; HEPARIN; LETROZOLE; LEVOTHYROXINE; LITHIUM CARBONATE; LOOP DIURETIC AGENT; METHOTREXATE; MORPHINE; NEUROLEPTIC AGENT; OPIATE; PLACEBO; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZOLEDRONIC ACID; ESTROGEN; GONADORELIN; THYROXINE;

ANTICHOLINERGIC EFFECT; ANTIINFLAMMATORY ACTIVITY; ATAXIA; BONE DENSITY; BONE REMODELING; CALCIUM URINE LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DIZZINESS; DRUG MECHANISM; DRUG MEGADOSE; EPILEPSY; ESTROGEN BLOOD LEVEL; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; HYPERPROLACTINEMIA; LEG FRACTURE; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PROSTATE CANCER; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SEDATION; SEX DIFFERENCE; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG POTENTIATION; FEMALE; MALE; PHYSIOLOGY;

AROMATASE INHIBITORS; BONE REMODELING; ESTROGENS; FEMALE; GLUCOCORTICOIDS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; OSTEOPOROSIS; THYROXINE;

EID: 44949208597     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-008-0019-4     Document Type: Review

References (66)

1. Mittan D, Lee S, Miller E, et al.: Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002, 87:3656-3661.
2. Daniell HW, Tam HW: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000, 163:181-186.
3. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 152:154-164.
4. Diamond TH, Hiagno CS, Smith MR, et al.: Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004, 100:892-899.
5. Michaelson MD, Kaufman DS, Lee H, et al.: Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007, 25:1038-1042.
6. Fernandez H, Lucas C, Hedon B, et al.: One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double blind trial. Human Reprod 2004, 19:1465-1471.
7. Howell A, Cuzick J, Baum M, et al.; the ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
8. Goss PE, Ingle JN, Robert NJ, et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349:1793-1802.
9. Coombes RC, Hall E, Gibson LJ, et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1092.
10. Coleman RE, Banks LM, Girgis SI, et al.: Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women in early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled study. Lancet Oncol 2007, 8:119-127.
11. Brufsky A, Harker WG, Beck JT, et al.: Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007, 25:829-836.
12. Vestergaard P: Epilepsy, osteoporosis and fracture risk - a meta-analysis. Acta Neurol Scand 2005, 112:277-286.
13. Omdahl JL, Morris HA, May BK: Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annual Rev Nutr 2002, 22:139-166.
14. Sato Y, Kondo I, Ishida S, et al.: Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001, 57:445-449.
15. Persson HB, Alberts KA, Farahmand BY, Tomson T: Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 2002, 43:768-772.
16. Vestergaard P, Tigaran S, Rejnmark L, et al.: Fracture risk is increased in epilepsy. Acta Neurol Scand 1999, 99:269-275.
17. Vestergaard P, Rejnmark L, Mosekilde L: Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004, 45:1330-1337.
18. Valmadrid C, Voorhees C, Litt B, Schnever CR: Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 2001, 58:1369-1374.
19. Whooley MA, Kip KE, Cauley JA, et al.: Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999, 159:484-490.
20. Mussolino ME, Jonas BS, Looker AC: Depression and bone mineral density in young adults: results from NHANES III. Psychosom Med 2004, 66:533-537.
21. Eskandari F, Martinez PE, Torvik S, et al.: Low bone mass in premenopausal women with depression Arch Intern Med 2007, 167:2329-2336.
22. Hubbard R, Farrington P, Smith C, et al.: Exposure to tricyclic and selective serotonin uptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 2003, 158:77-84.
23. Vestergaard P, Rejnmark L, Mosekilde L: Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 2006, 17:807-816.
24. Bliziotes M Gunness M, Eshleman A, Wiren K: The role of dopamine and serotonin in regulating bone mass and strength: studies on dopamine and serotonin transporter null mice. J Musculoskelet Neuronal Interact 2002, 3:291-295.
25. Richards JB, Papaioannou A, Adachi JD, et al.: Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007, 167:188-194.
26. Haney EM, Chan BK, Diem SJ, et al.: Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007, 167:1246-1251.
27. Diem SJ, Blackwell TL, Stone KL, et al.: Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007, 167:1240-1245.
28. Perez-Castrillon JL, Olmos JM, Gomez JJ, et al.: Expression of opioid eceptors in osteoblast-like MG 63 cells, and effects of different opioid agonists on alkaline phosphatase and osteocalcin secretion by these cells. Neuroendocrinology 2000, 72:187-194.
29. Ensrud KE, Blackwell T, Mangione CM, et al.: Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003, 163:949-957.
30. Vestergaard P, Rejnmark L, Mosekilde L: Fracture risk associated with use of morphine and opiates. J Intern Med 2006, 260:76-87.
31. Halbreich U, Rojansky N, Palter S, et al.: Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995, 57:485-491.
32. O'Keane V, Meaney AM: Antipsychotics drugs, a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 2005, 25:26-31.
33. Bilici M, Cakirbay H, Guler M, et al.: Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci 2002, 112:317-322.
34. Mak TW, Shek CC, Chow CC, et al.: Effects of lithium therapy on bone mineral metabolism: a two year prospective longitudinal study. J Clin Endocrinol Metab 1998, 83:3857-3859.
35. Clément-Lacroix P, Ai M, Morvan F, et al.: Lrp5-independent activation of Wnt signalling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A 2005, 102:17406-17411.
36. Cohen O, Rais T, Lepkifker E, Vered I: Lithium carbonate therapy is not a risk factor for osteoporosis. Horm Metab Res 1998, 30:954-957.
37. Wilting I, de Vries F, Thio BM, et al.: Lithium use and the risk of fractures. Bone 2007, 40:1252-1258.
38. Vestergaard P, Rejnmark L, Mosekilde L: Reduced relative risk of fracture among users of lithium. Calcif Tissue Int 2005, 77:1-8.
39. Szulc P, Arlot M, Chapuy MC, et al.: Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res 1994, 9:1591-1595.
40. Caraballo PJ, Gabriel SE, Castro MR, et al.: Changes in bone density after exposure to oral anticoagulants: a meta-analysis. Osteoporos Int 1999, 5:441-448.
41. Jamal SA, Browner WS, Bauer DC, Cummings SR: Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1998, 128:829-832.
42. Caraballo PJ, Heit JA, Atkinson EJ, et al.: Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med 1999, 159:1750-1756.
43. Renjmark L, Vestergaard P, Mosekilde L: Fracture risk in users of oral anticoagulants: a nationwide case-control study. Int J Cardiol 2007, 118:338-344.
44. Wawrzynska L, Przedlacki J, Hajduk B, et al.: Low-molecular-weight heparins, acenocoumarol and bone density. Haemostasis 2001, 31:69-70.
45. Handschin AE, Trentz OA, Hoerstrup SP, et al.: Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg 2005, 92:177-183.
46. Rajgopal R, Bear M, Butcher MK, Shaughnessy SG: The effects of heparin and low molecular weight heparins on bone. Thromb Res 2007, [Epub ahead of print].
47. Uzzan B, Campos J, Cucherat M, et al.: Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996, 81:4278-4289.
48. Faber J, Galloe AM: Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994, 130:350-356.
49. Greenspan SL, Greenspan FS: The effect of thyroid hormone on skeletal integrity. Ann Intern Med 1999, 130:750-758.
50. Bauer DC, Nevitt MC, Ettinger B, Stone K: Low thyrotropin levels are not associated with bone loss in older women: a prospective study. J Clin Endocrinol Metab 1997, 82:2931-2936.
51. Ross DS: Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinically hypothyroidism: a randomized, prospective study. Am J Med 1993, 95:385-388.
52. Rzonca SO, Suva LJ, Gaddy D, et al.: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145:401-406.
53. Watanabe S, Takeuchi Y, Fukumoto S, et al.: Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Res 2003, 21:166-171.
54. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al.: Thiazolidinedione (TZD) use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006, 91:3349-3354.
55. Short R: Fracture risk is a class effect of glitazones. BMJ 2007, 334:551.
56. Rejnmark L, Vestergaard P, Heickendorff L, et al.: Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res 2006, 21:163-170.
57. Rejnmark L, Vestergaard P, Mosekilde L: Fracture risk in patients treated with loop diuretics. J Inter Med 2006, 259:117-124.
58. Vestergaard P, Rejnmark L, Mosekilde L: Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006, 79:76-83.
59. Yang YN, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296:2947-2953.
60. Farina C, Gagliardi S: Selective inhibition of osteoclast vacuolar H(+)-AtPase. Curr Pharm Des 2002, 8:2033-2048.
61. Visentin L, Dodds RA, Valente M, et al.: A selective inhibitor of the osteoclastic V-H(+)-Atpase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J Clin Invest 2000, 106:309-318.
62. Minaur NJ, Kounali D, Vedi S, et al.: Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology 2002, 41:741-749.
63. Rejnmark L, Vesterggard P, Mosekilde L: Fracture risk in patients treated with amiodarone or digoxin for cardiac arrhythmias: a nation-wide case-control study. Osteoporos Int 2007, 18:409-417.
64. Erben RG, Brunner KS, Breig B, et al.: Skeletal effects of cyclosporin A are gender related in rats. Endocrinology 2003, 144:40-49.
65. Monegal A, Navasa M, Guanabens B, et al.: Bone mass and mineral metabolism in liver transplant treated with FK 506 or cyclosporine A. Calcif Tissue Int 2001, 68:83-86.
66. Amiel C, Ostertag A, Slama L, et al.: BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 2004, 19:402-409.